Oncolytic Virus Therapy Market By Virus Type (Adenovirus, Herpes Simplex Virus (HSV), Vaccinia Virus, Newcastle Disease Virus (NDV), Reovirus, Others), By Application (Melanoma, Breast Cancer, Lung Cancer, Colorectal Cancer, Pancreatic Cancer, Others), By Therapy Type (Monotherapy, Combination Therapy), By Route of Administration (Intratumoral, Intravenous, Others), By End-user (Hospitals, Cancer Research Institutes, Specialty Clinics, Others.), Global Market Size, Segmental analysis, Regional Overview, Company share analysis, Leading Company Profiles And Market Forecast, 2025 – 2035

---

Table of Contents

1. Methodology & Report Coverage

1.1. Definition & Objective

1.2. Market Evaluation & Forecast Parameter

1.3. Research Methodology

1.4. Data Validation Sources

1.4.1. Secondary Research

1.4.2. Primary Research

2. Market Overview

3. Oncolytic Virus Market: Market Dynamics

3.1. Executive Summary

3.2. Market Driving Factors

3.2.1. Oncolytic viruses act as both direct cancer killers and immune response activators.

3.2.2. Rising number of cancer cases globally, particularly aggressive and treatment-resistant tumors.

3.2.3. FDA and EMA support for breakthrough therapies like T-VEC, encouraging pipeline development

3.3. Key industry pitfalls & challenges

3.3.1. High cost and complexity of clinical trials involving live viral agents.

3.3.2. Manufacturing challenges related to virus purification, storage, and scalability.

3.3.3. Limited patient awareness and acceptance of virus-based therapies.

3.4. Market Opportunities

3.4.1. Development of virus therapies for rare and pediatric cancers with unmet needs.

3.4.2. Use in neoadjuvant or adjuvant cancer treatment settings to prevent recurrence.

3.4.3. Advancements in AI and machine learning to design and predict viral behavior.

3.5. Porter’s Five Forces Analysis

3.6. PESTLE Analysis

3.7. Regulatory landscape

3.8. Investment Landscape

3.9. ESG Scenario

3.10. Competitive landscape

3.10.1. Company Market Share

3.10.2. Market Positioning

3.10.3. Strategy framework

3.10.4. Recent Acquisitions & Mergers

4. Oncolytic Virus Market, Virus Type Segment Analysis

4.1. Overview Dynamics

4.1.1. Market Revenue Share, By Virus Type, 2025 & 2035

4.1.2. Key Market Trends, Growth Factors, & Opportunities

4.2. Adenovirus

4.2.1. Market Size and Forecast, 2025-2035 (USD Million)

4.3. Herpes Simplex Virus (HSV)

4.3.1. Market Size and Forecast, 2025-2035 (USD Million)

4.4. Vaccinia Virus

4.4.1. Market Size and Forecast, 2025-2035 (USD Million)

4.5. Newcastle Disease Virus (NDV)

4.5.1. Market Size and Forecast, 2025-2035 (USD Million)

4.6. Reovirus

4.6.1. Market Size and Forecast, 2025-2035 (USD Million)

4.7. Others

4.7.1. Market Size and Forecast, 2025-2035 (USD Million)

5. Oncolytic Virus Market, Application Segment Analysis

5.1. Overview

5.1.1. Market Revenue Share, By Application, 2025 & 2035

5.1.2. Key Market Trends, Growth Factors, & Opportunities

5.2. Melanoma

5.2.1. Market Size and Forecast, 2025-2035 (USD Million)

5.3. Breast Cancer

5.3.1. Market Size and Forecast, 2025-2035 (USD Million)

5.4. Lung Cancer

5.4.1. Market Size and Forecast, 2025-2035 (USD Million)

5.5. Colorectal Cancer

5.5.1. Market Size and Forecast, 2025-2035 (USD Million)

5.6. Pancreatic Cancer

5.6.1. Market Size and Forecast, 2025-2035 (USD Million)

5.7. Others

5.7.1. Market Size and Forecast, 2025-2035 (USD Million)

6. Oncolytic Virus Market, Therapy Type Segment Analysis

6.1. Overview

6.1.1. Market Revenue Share, By Therapy Type, 2025 & 2035

6.1.2. Key Market Trends, Growth Factors, & Opportunities

6.2. Monotherapy

6.2.1. Market Size and Forecast, 2025-2035 (USD Million)

6.3. Combination Therapy

6.3.1. Market Size and Forecast, 2025-2035 (USD Million)

7. Oncolytic Virus Market, Route of Administration Segment Analysis

7.1. Overview

7.1.1. Market Revenue Share, By Route of Administration, 2025 & 2035

7.1.2. Key Market Trends, Growth Factors, & Opportunities

7.2. Intratumoral

7.2.1. Market Size and Forecast, 2025-2035 (USD Million)

7.3. Intravenous

7.3.1. Market Size and Forecast, 2025-2035 (USD Million)

7.4. Others

7.4.1. Market Size and Forecast, 2025-2035 (USD Million)

8. Oncolytic Virus Market, End-user Segment Analysis

8.1. Overview

8.1.1. Market Revenue Share, By End-user, 2025 & 2035

8.1.2. Key Market Trends, Growth Factors, & Opportunities

8.2. Hospitals

8.2.1. Market Size and Forecast, 2025-2035 (USD Million)

8.3. Cancer Research Institutes

8.3.1. Market Size and Forecast, 2025-2035 (USD Million)

8.4. Specialty Clinics

8.4.1. Market Size and Forecast, 2025-2035 (USD Million)

8.5. Others

8.5.1. Market Size and Forecast, 2025-2035 (USD Million)

9. Oncolytic Virus Market, Region Segment Analysis

9.1. Overview

9.1.1. Global Market Revenue Share, By Region, 2025 & 2035

9.1.2. Global Market Revenue, By Region, 2025-2035 (USD Million)

9.2. North America

9.2.1. North America Market Revenue, By Country, 2025-2035 (USD Million)

9.2.2. North America Market Revenue, By Virus Type, 2025-2035

9.2.3. North America Market Revenue, By Application, 2025-2035

9.2.4. North America Market Revenue, By Therapy Type, 2025-2035

9.2.5. North America Market Revenue, By Route of Administration, 2025-2035

9.2.6. North America Market Revenue, By End-user, 2025-2035

9.2.7. The U.S.

9.2.7.1. U.S. Market Revenue, By Virus Type, 2025-2035

9.2.7.2. U.S. Market Revenue, By Application, 2025-2035

9.2.7.3. U.S. Market Revenue, By Therapy Type, 2025-2035

9.2.7.4. U.S. Market Revenue, By Route of Administration, 2025-2035

9.2.7.5. U.S. Market Revenue, By End-user, 2025-2035

9.2.8. Canada

9.2.8.1. Canada Market Revenue, By Virus Type, 2025-2035

9.2.8.2. Canada Market Revenue, By Application, 2025-2035

9.2.8.3. Canada Market Revenue, By Therapy Type, 2025-2035

9.2.8.4. Canada Market Revenue, By Route of Administration, 2025-2035

9.2.8.5. Canada Market Revenue, By End-user, 2025-2035

9.3. Europe

9.3.1. Europe Market Revenue, By Country, 2025-2035 (USD Million)

9.3.2. Europe Market Revenue, By Virus Type, 2025-2035

9.3.3. Europe Market Revenue, By Application, 2025-2035

9.3.4. Europe Market Revenue, By Therapy Type, 2025-2035

9.3.5. Europe Market Revenue, By Route of Administration, 2025-2035

9.3.6. Europe Market Revenue, By End-user, 2025-2035

9.3.7. Germany

9.3.7.1. Germany Market Revenue, By Virus Type, 2025-2035

9.3.7.2. Germany Market Revenue, By Application, 2025-2035

9.3.7.3. Germany Market Revenue, By Therapy Type, 2025-2035

9.3.7.4. Germany Market Revenue, By Route of Administration, 2025-2035

9.3.7.5. Germany Market Revenue, By End-user, 2025-2035

9.3.8. France

9.3.8.1. France Market Revenue, By Virus Type, 2025-2035

9.3.8.2. France Market Revenue, By Application, 2025-2035

9.3.8.3. France Market Revenue, By Therapy Type, 2025-2035

9.3.8.4. France Market Revenue, By Route of Administration, 2025-2035

9.3.8.5. France Market Revenue, By End-user, 2025-2035

9.3.9. U.K.

9.3.9.1. U.K. Market Revenue, By Virus Type, 2025-2035

9.3.9.2. U.K. Market Revenue, By Application, 2025-2035

9.3.9.3. U.K. Market Revenue, By Therapy Type, 2025-2035

9.3.9.4. U.K. Market Revenue, By Route of Administration, 2025-2035

9.3.9.5. U.K. Market Revenue, By End-user, 2025-2035

9.3.10. Italy

9.3.10.1. Italy Market Revenue, By Virus Type, 2025-2035

9.3.10.2. Italy Market Revenue, By Application, 2025-2035

9.3.10.3. Italy Market Revenue, By Therapy Type, 2025-2035

9.3.10.4. Italy Market Revenue, By Route of Administration, 2025-2035

9.3.10.5. Italy Market Revenue, By End-user, 2025-2035

9.3.11. Spain

9.3.11.1. Spain Market Revenue, By Virus Type, 2025-2035

9.3.11.2. Spain Market Revenue, By Application, 2025-2035

9.3.11.3. Spain Market Revenue, By Therapy Type, 2025-2035

9.3.11.4. Spain Market Revenue, By Route of Administration, 2025-2035

9.3.11.5. Spain Market Revenue, By End-user, 2025-2035

9.3.12. Rest of Europe

9.3.12.1. Rest of Europe Market Revenue, By Virus Type, 2025-2035

9.3.12.2. Rest of Europe Market Revenue, By Application, 2025-2035

9.3.12.3. Rest of Europe Market Revenue, By Therapy Type, 2025-2035

9.3.12.4. Rest of Europe Market Revenue, By Route of Administration, 2025-2035

9.3.12.5. Rest of Europe Market Revenue, By End-user, 2025-2035

9.4. Asia Pacific

9.4.1. Asia Pacific Market Revenue, By Country, 2025-2035 (USD Million)

9.4.2. Asia Pacific Market Revenue, By Virus Type, 2025-2035

9.4.3. Asia Pacific Market Revenue, By Application, 2025-2035

9.4.4. Asia Pacific Market Revenue, By Therapy Type, 2025-2035

9.4.5. Asia Pacific Market Revenue, By Route of Administration, 2025-2035

9.4.6. Asia Pacific Market Revenue, By End-user, 2025-2035

9.4.7. China

9.4.7.1. China Market Revenue, By Virus Type, 2025-2035

9.4.7.2. China Market Revenue, By Application, 2025-2035

9.4.7.3. China Market Revenue, By Therapy Type, 2025-2035

9.4.7.4. China Market Revenue, By Route of Administration, 2025-2035

9.4.7.5. China Market Revenue, By End-user, 2025-2035

9.4.8. Japan

9.4.8.1. Japan Market Revenue, By Virus Type, 2025-2035

9.4.8.2. Japan Market Revenue, By Application, 2025-2035

9.4.8.3. Japan Market Revenue, By Therapy Type, 2025-2035

9.4.8.4. Japan Market Revenue, By Route of Administration, 2025-2035

9.4.8.5. Japan Market Revenue, By End-user, 2025-2035

9.4.9. India

9.4.9.1. India Market Revenue, By Virus Type, 2025-2035

9.4.9.2. India Market Revenue, By Application, 2025-2035

9.4.9.3. India Market Revenue, By Therapy Type, 2025-2035

9.4.9.4. India Market Revenue, By Route of Administration, 2025-2035

9.4.9.5. India Market Revenue, By End-user, 2025-2035

9.4.10. Australia

9.4.10.1. Australia Market Revenue, By Virus Type, 2025-2035

9.4.10.2. Australia Market Revenue, By Application, 2025-2035

9.4.10.3. Australia Market Revenue, By Therapy Type, 2025-2035

9.4.10.4. Australia Market Revenue, By Route of Administration, 2025-2035

9.4.10.5. Australia Market Revenue, By End-user, 2025-2035

9.4.11. South Korea

9.4.11.1. South Korea Market Revenue, By Virus Type, 2025-2035

9.4.11.2. South Korea Market Revenue, By Application, 2025-2035

9.4.11.3. South Korea Market Revenue, By Therapy Type, 2025-2035

9.4.11.4. South Korea Market Revenue, By Route of Administration, 2025-2035

9.4.11.5. South Korea Market Revenue, By End-user, 2025-2035

9.4.12. Singapore

9.4.12.1. Singapore Market Revenue, By Virus Type, 2025-2035

9.4.12.2. Singapore Market Revenue, By Application, 2025-2035

9.4.12.3. Singapore Market Revenue, By Therapy Type, 2025-2035

9.4.12.4. Singapore Market Revenue, By Route of Administration, 2025-2035

9.4.12.5. Singapore Market Revenue, By End-user, 2025-2035

9.4.13. Rest of Asia Pacific

9.4.13.1. Rest of Asia Pacific Market Revenue, By Virus Type, 2025-2035

9.4.13.2. Rest of Asia Pacific Market Revenue, By Application, 2025-2035

9.4.13.3. Rest of Asia Pacific Market Revenue, By Therapy Type, 2025-2035

9.4.13.4. Rest of Asia Pacific Market Revenue, By Route of Administration, 2025-2035

9.4.13.5. Rest of Asia Pacific Market Revenue, By End-user, 2025-2035

9.5. Latin America

9.5.1. Latin America Market Revenue, By Country, 2025-2035 (USD Million)

9.5.2. Latin America Market Revenue, By Virus Type, 2025-2035

9.5.3. Latin America Market Revenue, By Application, 2025-2035

9.5.4. Latin America Market Revenue, By Therapy Type, 2025-2035

9.5.5. Latin America Market Revenue, By Route of Administration, 2025-2035

9.5.6. Latin America Market Revenue, By End-user, 2025-2035

9.5.7. Brazil

9.5.7.1. Brazil Market Revenue, By Virus Type, 2025-2035

9.5.7.2. Brazil Market Revenue, By Application, 2025-2035

9.5.7.3. Brazil Market Revenue, By Therapy Type, 2025-2035

9.5.7.4. Brazil Market Revenue, By Route of Administration, 2025-2035

9.5.7.5. Brazil Market Revenue, By End-user, 2025-2035

9.5.8. Argentina

9.5.8.1. Argentina Market Revenue, By Virus Type, 2025-2035

9.5.8.2. Argentina Market Revenue, By Application, 2025-2035

9.5.8.3. Argentina Market Revenue, By Therapy Type, 2025-2035

9.5.8.4. Argentina Market Revenue, By Route of Administration, 2025-2035

9.5.8.5. Argentina Market Revenue, By End-user, 2025-2035

9.5.9. Mexico

9.5.9.1. Mexico Market Revenue, By Virus Type, 2025-2035

9.5.9.2. Mexico Market Revenue, By Application, 2025-2035

9.5.9.3. Mexico Market Revenue, By Therapy Type, 2025-2035

9.5.9.4. Mexico Market Revenue, By Route of Administration, 2025-2035

9.5.9.5. Mexico Market Revenue, By End-user, 2025-2035

9.5.10. Rest of Latin America

9.5.10.1. Rest of Latin America Market Revenue, By Virus Type, 2025-2035

9.5.10.2. Rest of Latin America Revenue, By Application, 2025-2035

9.5.10.3. Rest of Latin America Market Revenue, By Therapy Type, 2025-2035

9.5.10.4. Rest of Latin America Market Revenue, By Route of Administration, 2025-2035

9.5.10.5. Rest of Latin America Market Revenue, By End-user, 2025-2035

9.6. MEA

9.6.1. MEA Market Revenue, By Country, 2025-2035 (USD Million)

9.6.2. MEA Market Revenue, By Virus Type, 2025-2035

9.6.3. MEA Market Revenue, By Application, 2025-2035

9.6.4. MEA Market Revenue, By Therapy Type, 2025-2035

9.6.5. MEA Market Revenue, By Route of Administration, 2025-2035

9.6.6. MEA Market Revenue, By End-user, 2025-2035

9.6.7. GCC Countries

9.6.7.1. GCC Countries Market Revenue, By Virus Type, 2025-2035

9.6.7.2. GCC Countries Market Revenue, By Application, 2025-2035

9.6.7.3. GCC Countries Market Revenue, By Therapy Type, 2025-2035

9.6.7.4. GCC Countries Market Revenue, By Route of Administration, 2025-2035

9.6.7.5. GCC Countries Market Revenue, By End-user, 2025-2035

9.6.8. South Africa

9.6.8.1. South Africa Market Revenue, By Virus Type, 2025-2035

9.6.8.2. South Africa Market Revenue, By Application, 2025-2035

9.6.8.3. South Africa Market Revenue, By Therapy Type, 2025-2035

9.6.8.4. South Africa Market Revenue, By Route of Administration, 2025-2035

9.6.8.5. South Africa Market Revenue, By End-user, 2025-2035

9.6.9. Rest of Middle-East & Africa

9.6.9.1. Rest of Middle-East & Africa Market Revenue, By Virus Type, 2025-2035

9.6.9.2. Rest of Middle-East & Africa Market Revenue, By Application, 2025-2035

9.6.9.3. Rest of Middle-East & Africa Market Revenue, By Therapy Type, 2025-2035

9.6.9.4. Rest of Middle-East & Africa Market Revenue, By Route of Administration, 2025-2035

9.6.9.5. Rest of Middle-East & Africa Market Revenue, By End-user, 2025-2035

10. Company Profile

10.1. Amgen Inc.

10.1.1. Business Overview

10.1.2. Financial Performance

10.1.3. Product/Service Offerings

10.1.4. Strategies & recent developments

10.1.5. SWOT Analysis

10.2. Oncolytics Biotech Inc.

10.2.1. Business Overview

10.2.2. Financial Performance

10.2.3. Product/Service Offerings

10.2.4. Strategies & recent developments

10.2.5. SWOT Analysis

10.3. SillaJen Inc.

10.3.1. Business Overview

10.3.2. Financial Performance

10.3.3. Product/Service Offerings

10.3.4. Strategies & recent developments

10.3.5. SWOT Analysis

10.4. Vyriad Inc.

10.4.1. Business Overview

10.4.2. Financial Performance

10.4.3. Product/Service Offerings

10.4.4. Strategies & recent developments

10.4.5. SWOT Analysis

10.5. Targovax ASA

10.5.1. Business Overview

10.5.2. Financial Performance

10.5.3. Product/Service Offerings

10.5.4. Strategies & recent developments

10.5.5. SWOT Analysis

10.6. Lokon Pharma AB

10.6.1. Business Overview

10.6.2. Financial Performance

10.6.3. Product/Service Offerings

10.6.4. Strategies & recent developments

10.6.5. SWOT Analysis

10.7. Transgene SA

10.7.1. Business Overview

10.7.2. Financial Performance

10.7.3. Product/Service Offerings

10.7.4. Strategies & recent developments

10.7.5. SWOT Analysis

10.8. PsiOxus Therapeutics

10.8.1. Business Overview

10.8.2. Financial Performance

10.8.3. Product/Service Offerings

10.8.4. Strategies & recent developments

10.8.5. SWOT Analysis

10.9. ViroCure Inc.

10.9.1. Business Overview

10.9.2. Financial Performance

10.9.3. Product/Service Offerings

10.9.4. Strategies & recent developments

10.9.5. SWOT Analysis

10.10. Virttu Biologics Ltd.

10.10.1. Business Overview

10.10.2. Financial Performance

10.10.3. Product/Service Offerings

10.10.4. Strategies & recent developments

10.10.5. SWOT Analysis

10.11. Genelux Corporation

10.11.1. Business Overview

10.11.2. Financial Performance

10.11.3. Product/Service Offerings

10.11.4. Strategies & recent developments

10.11.5. SWOT Analysis

10.12. BioVex Inc.

10.12.1. Business Overview

10.12.2. Financial Performance

10.12.3. Product/Service Offerings

10.12.4. Strategies & recent developments

10.12.5. SWOT Analysis

10.13. Replimune Group Inc.

10.13.1. Business Overview

10.13.2. Financial Performance

10.13.3. Product/Service Offerings

10.13.4. Strategies & recent developments

10.13.5. SWOT Analysis

10.14. CG Oncology Inc.

10.14.1. Business Overview

10.14.2. Financial Performance

10.14.3. Product/Service Offerings

10.14.4. Strategies & recent developments

10.14.5. SWOT Analysis

10.15. Virogin Biotech Ltd.

10.15.1. Business Overview

10.15.2. Financial Performance

10.15.3. Product/Service Offerings

10.15.4. Strategies & recent developments

10.15.5. SWOT Analysis